1. bookVolumen 26 (2018): Heft 2 (April 2018)
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
2284-5623
Erstveröffentlichung
08 Aug 2013
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch
access type Uneingeschränkter Zugang

Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome

Online veröffentlicht: 17 May 2018
Volumen & Heft: Volumen 26 (2018) - Heft 2 (April 2018)
Seitenbereich: 243 - 250
Eingereicht: 16 Nov 2017
Akzeptiert: 14 Feb 2018
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
2284-5623
Erstveröffentlichung
08 Aug 2013
Erscheinungsweise
4 Hefte pro Jahr
Sprachen
Englisch
Abstract

Backgroud. Which factors determine venous thrombotic events in some antiphospholipid syndrome (APS) patients and arterial thrombosis or conditions related to pregnancy in others has not been established yet. Purpose. The aim of this study was to search the antiphospholipid antibodies (APLAs) correlates in regard to deep vein thrombosis (DVT) in patients with systemic lupus erythematosus (SLE) and APS. Methods. Twenty-nine patients fulfilling the criteria of both SLE and APS were included. Complete anamnesis and clinical examination was performed on inclusion. Also, for all patients, disease activity was assessed by the SLEDAI score. An extended APLAs profile, ten Abs, was searched. Results. The titers of IgG anticardiolipin (aCL), IgG anti-β2 glycoprotein I (aβ2GPI), IgG antiphosphatidylethanolamine (aPE), and also of IgG antiprothrombin (aPT) were significant higher in patients with DVT history. After analysis by ROC curve and univariate logistic regression, the strongest association was found for IgG aPE. Also, in multivariate analysis, SLEDAI score correlated with the DVT antecedents. Conclusions. IgG aPE might be involved in DVT pathogenic pathways in patients with SLE and APS as their titers remain significantly higher in patients with previous DVT. Lupus patients with DVT events represent a subgroup of patients with more severe underlying pathology.

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x10.1111/j.1538-7836.2006.01753.x16420554DOI öffnenSearch in Google Scholar

2. Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford). 2013 Aug;52(8):1358-67. DOI: 10.1093/rheumatology/ket12610.1093/rheumatology/ket12623502076Search in Google Scholar

3. Staub HL, Bertolaccini ML, Khamashta MA. Anti- phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev. 2012 Dec;12(2):230-4. DOI: 10.1016/j.autrev.2012.07.00810.1016/j.autrev.2012.07.00822796282DOI öffnenSearch in Google Scholar

4. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014 Sep;13(9):917-30. DOI: 10.1016/j.autrev.2014.05.00110.1016/j.autrev.2014.05.00124824074DOI öffnenSearch in Google Scholar

5. Sestak A, O’Neil KM. Familial lupus and antiphospholipid syndrome. Lupus. 2007; 16(8): 556-63. DOI: 10.1177/0961203307078071 10.1177/096120330707807117711888Search in Google Scholar

6. Bertolaccini ML, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GR, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005 Nov;64(11):1639-43. DOI: 10.1136/ard.2005.03582410.1136/ard.2005.035824175525915817655DOI öffnenSearch in Google Scholar

7. Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, Poor G, et al. Identification of rare anti-phospholipid/ protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity. 2009 Sep;42(6):497-506. DOI: 10.1080/0891693090288273110.1080/0891693090288273119626489DOI öffnenSearch in Google Scholar

8. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. DOI: 10.1002/art.3447310.1002/art.34473340931122553077Search in Google Scholar

9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40. DOI: 10.1002/art.178035060610.1002/art.17803506061599520DOI öffnenSearch in Google Scholar

10. Gavris C, Anghel M, Radoi M, Gheorghita E, Duca L, Pamfil G, et al. Risk of recurrent thrombosis related to antiphospholipid antibodies, soluble CD40L and P selectin serum levels in patients with antiphospholipid syndrome secondary to systemic lupus eritematosus. RRML. 2010 Sept;3(4):23-28.Search in Google Scholar

11. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467-73. DOI: 10.1177/09612033970060051010.1177/0961203397006005109229367DOI öffnenSearch in Google Scholar

12. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002 Dec;29(12):2531-6.Search in Google Scholar

13. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort. Lupus. 2010 Apr;19(4):419-23. DOI: 10.1177/096120330936054110.1177/096120330936054120353980DOI öffnenSearch in Google Scholar

14. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003 Mar;101(5):1827-32. DOI: 10.1182/blood-2002-02-044110.1182/blood-2002-02-044112393574DOI öffnenSearch in Google Scholar

15. Bertolaccini ML. Antibodies to prothrombin. Lupus. 2012 Jun;21(7):729-31. DOI: 10.1177/096120331244329910.1177/096120331244329922635215DOI öffnenSearch in Google Scholar

16. Bertolaccini ML, Murru V, Sciascia S, Sanna G, Khamashta MA. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res. 2012 Dec;130(6):914-8. DOI: 10.1016/j.thromres.2012.06.00810.1016/j.thromres.2012.06.00823079292Search in Google Scholar

17. Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007 Jun;97(6):949-54. DOI: 10.1160/TH06-10-060410.1160/TH06-10-0604DOI öffnenSearch in Google Scholar

18. Sanmarco M, Bardin N. The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome. Lupus. 2012 Jun;21(7):727-8. DOI: 10.1177/096120331243727210.1177/096120331243727222635214DOI öffnenSearch in Google Scholar

19. Matta BN, Uthman I, Taher AT, Khamashta MA. The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. Expert Rev Clin Immunol. 2013 Jul;9(7):659-68. DOI: 10.1586/1744666X.2013.81118310.1586/1744666X.2013.81118323899236DOI öffnenSearch in Google Scholar

Empfohlene Artikel von Trend MD

Planen Sie Ihre Fernkonferenz mit Scienceendo